Toy Andrew sold $1.3M of CLOV

Toy Andrew (Chief Executive Officer) sold 318,806 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.19 ($1.34M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Toy Andrew
Published Oct 2, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
medium confidence
Mentioned
$CLOV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The CEO's sale may signal short‑term weakness, but the long‑term impact depends on broader company fundamentals.

02

Market read

Insider sell of over $1M by the CEO is a material event for CLOV, potentially prompting short‑term price adjustments.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: after filing today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering timely insight into insider sentiment.

Company-level read

Ticker impact

$CLOVBearishMedium confidence
Context

CEO Toy Andrew sold 318,806 shares for $1.33M via a 10b5‑1 plan, reducing his stake to 9.14M shares.

Expected impact

likely downward pressure as investors price in the insider sell

Evidence & confidence

A $1.3M sale by the chief executive is material for a mid‑cap biotech, often interpreted as a lack of confidence or liquidity need, which can trigger short‑term selling.

Market effects

May raise concerns for other biotech firms with insider sales, but limited sector-wide impact.

Primarily U.S. market; no broader regional effect.

Low global relevance; confined to CLOV shareholders.

Counterpoint

The sale could be a routine liquidity move unrelated to company outlook; price may remain stable.

Key entities

  • Toy Andrew

    Chief Executive Officer of Clover Health Investments, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.